Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Autoantibodies in Kidney Diseases
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.
Towards New Promising Discoveries for Lung Cancer Patients: A Selection of Papers from the First Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA)
This Special Issue of Cancers (Basel) is mainly dedicated to selecting papers from the talks given during the first Joint Meeting on Lung Cancer (JMLC) between the MD Anderson Cancer Center (Houston, Texas USA) and the Hospital University Federation (HUF) OncoAge (University Côte d’Azur, Nice, France) (Nice, September 2018). The central theme of JMLC is to discuss new advances and exchange ideas regarding lung cancer. Notably, the talks covered different topics on new therapeutic strategies (targeted therapy and immuno-oncology), molecular and cellular biology, biomarkers, and the epidemiology of lung cancer. Special attention was also given to lung cancer in elderly patients. The articles published in this Special Issue covered subjects such as the assessment of new biomarkers and new approaches for the early detection of lung cancer, epidemiological data, and emphasized a place for the newly characterized cellular pathways in lung cancer, which opens room for therapeutic perspectives for lung cancer patients.
COVID and Emerging Infectious Diseases
Over the last two years with the strain of coronavirus having a devastating effect on the world’s healthcare system and triggering a global "lockdown", one question that has emerged; What, or which infectious disease is going to hit us next? Many infectious diseases prevalent in humans and animals are caused by pathogens that once emerged from other animal hosts. In addition to these established or re-emerging infections, new infectious diseases periodically emerge. In extreme cases they may lead to pandemics as we currently are seeing. The increased urbanization and globalization of the world order with faster connectivity and traveling has further in-creased the risk factors for emerging...
Coronavirus Disease (COVID-19): Pathophysiology, Epidemiology, Clinical Management and Public Health Response, Volume II (volume I.A)
Almost nine months since the first recorded case, the novel betacoronovirus; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has now passed 18 million confirmed cases. The multi-disciplinary work of researchers worldwide has provided a far deeper understanding of COVID-19 pathogenesis, clinical treatment and outcomes, lethality, disease-spread dynamics, period of infectivity, containment interventions, as well as providing a wealth of relevant epidemiological data. With 27 vaccines currently undergoing human trials, and countries worldwide continuing to battle case numbers, or prepare for resurgences, the need for efficient, high-quality pipelines for peer-reviewed research remains as crucial as ever.
Immunogenicity of Proteins Used as Therapeutics
Topic Editor Susan Richards is an employee of Sanofi and owns stock in the corporation. Topic Editor Bernard Maillere declares economic support from pharmaceutical companies (Novartis, Sanofi, and UCB) in the frame of collaborations aiming to evaluate the recognition by human T cells of therapeutic proteins and antibodies.
